Dosimetry Data from Ph 3 COMPETE Trial Supports Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with GEP-NETs
“As the first company to conduct dosimetry in a large, randomized Phase 3 radiopharmaceutical trial in patients with Grade 1 or 2 GEP-NETs, we are encouraged by these findings, which align with the favorable therapeutic and safety profile of ¹⁷⁷Lu-edotreotide observed in our COMPETE trial,” said Dr. Andrew Cavey, chief executive officer of ITM. “This important dosimetry work would not have been possible without the support and cooperation of the investigators and, most importantly, the patients who participated in the trial.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.